Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Aug 22;13(8):e0200810.
doi: 10.1371/journal.pone.0200810. eCollection 2018.

Addressing the under-reporting of adverse drug reactions in public health programs controlling HIV/AIDS, Tuberculosis and Malaria: A prospective cohort study

Yohanna Kambai Avong  1 , Bolajoko Jatau  1 , Ritmwa Gurumnaan  1 , Nanfwang Danat  1 , James Okuma  1 , Istifanus Usman  1 , Dennis Mordi  1 , Blessing Ukpabi  1 , Gbenga Ayodele Kayode  1 , Saswata Dutt  1 , Osman El-Tayeb  2 , Bamgboye Afolabi  3 , Isah Ambrose  4 , Oche Agbaji  5 , Adeline Osakwe  6 , Ali Ibrahim  7 , Comfort Ogar  7 , Helga Nosiri  7 , Eunice B Avong  8 , Victor Adekanmbi  9 , Olalekan Uthman  10 , Alash'le Abimiku  1 , Yetunde O Oni  7 , Charles Olalekan Mensah  1 , Patrick Dakum  1 , Kamau Edward Mberu  11 , Olumide A T Ogundahunsi  11
Affiliations

Addressing the under-reporting of adverse drug reactions in public health programs controlling HIV/AIDS, Tuberculosis and Malaria: A prospective cohort study

Yohanna Kambai Avong et al. PLoS One. .

Abstract

Background: Adverse Drug Reactions (ADRs) are a major clinical and public health problem world-wide. The prompt reporting of suspected ADRs to regulatory authorities to activate drug safety surveillance and regulation appears to be the most pragmatic measure for addressing the problem. This paper evaluated a pharmacovigilance (PV) training model that was designed to improve the reporting of ADRs in public health programs treating the Human Immunodeficiency Virus (HIV), Tuberculosis (TB) and Malaria.

Methods: A Structured Pharmacovigilance and Training Initiative (SPHAR-TI) model based on the World Health Organization accredited Structured Operational Research and Training Initiative (SOR-IT) model was designed and implemented over a period of 12 months. A prospective cohort design was deployed to evaluate the outcomes of the model. The primary outcomes were knowledge gained and Individual Case Safety Reports (ICSR) (completed adverse drug reactions monitoring forms) submitted, while the secondary outcomes were facility based Pharmacovigilance Committees activated and health facility healthcare workers trained by the participants.

Results: Fifty-five (98%) participants were trained and followed up for 12 months. More than three quarter of the participants have never received training on pharmacovigilance prior to the course. Yet, a significant gain in knowledge was observed after the participants completed a comprehensive training for six days. In only seven months, 3000 ICSRs (with 100% completeness) were submitted, 2,937 facility based healthcare workers trained and 46 Pharmacovigilance Committees activated by the participants. Overall, a 273% increase in ICSRs submission to the National Agency for Food and Drug Administration and Control (NAFDAC) was observed.

Conclusion: Participants gained knowledge, which tended to increase the reporting of ADRs. The SPHAR-TI model could be an option for strengthening the continuous reporting of ADRs in public health programs in resource limited settings.

PubMed Disclaimer

Conflict of interest statement

The authors including those affiliated with commercial organization declare that they have no competing interest. The affiliation with Wise Health Services Limited does not alter our adherence to PLOS ONE policies on sharing data and materials (as detailed online in our guide for authors, http://journals.plos.org/plosone/s/competing-interests).

References

    1. Beijer HJ, Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. PharmWorld Sci. 2002; 24(2):46–54. - PubMed
    1. Einarson TR. Drug-related hospital admissions. Ann Pharmacother. 1993; 27(7–8):832–40. 10.1177/106002809302700702 - DOI - PubMed
    1. Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother. 2008; 42(7):1017–25. 10.1345/aph.1L037 - DOI - PubMed
    1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998; 279(15):1200 - PubMed
    1. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004; 329(7456):15–9. 10.1136/bmj.329.7456.15 - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources